Novan names Kelly Martin CEO

Novan announced a number of key leadership and talent advancements that add to the existing foundation of the company and enable its continued progress across key areas. Kelly Martin, who was appointed interim CEO in June of 2017, will no longer be serving in an interim capacity. Martin will work actively with the board of directors and leadership team of Novan to aggressively move the company forward. Of particular note, and in addition to the full breadth of responsibilities as the CEO, Martin will be directly responsible for shareholder and market interface, including current or potential shareholders, sell side analysts and other traditional or nontraditional providers of capital. From a clinical development organizational perspective, Novan has announced that Elizabeth Messersmith will be joining the company in the role of SVP of Clinical Operations on June 1, 2018. In this role, Messersmith will report to Paula Brown Stafford, chief development officer, and be responsible for the direction and execution of the company's broad and diverse clinical drug development programs. Messersmith joins Novan from Quark Pharmaceuticals, where she held the position of SVP, Clinical Operations and Data Management. Lastly, Novan's Board of Directors has appointed Andrew Novak, who has served most recently as the company's senior director of financial reporting and analysis, to the role of VP and chief accounting officer. Novak will serve as the company's principal accounting officer. Jeff Hunter, EVP, chief business officer and corporate secretary will continue to serve as the company's principal financial officer. Together, Hunter and Novak will lead and oversee the financial operations of Novan.